Articles

Soft tissue sarcomas (STS) are a group of rare mesenchymal tumours that can arise in patients of any age and in a variety of anatomic sites. It is estimated that STS make up 1% of all adult malignancies and that their incidence is on the rise. The lower limb is the most commonly affected site, with approximately 28% of STS arising there. With at least 50 different histologic subtypes, STS are considered highly heterogenous in terms of their histopathology and their tendency to metastasise. Undifferentiated pleomorphic sarcomas and liposarcomas are the most common histopathologic subtypes in adult patients.

This review provides a practical update of the role of imaging in every phase throughout the course of ovarian cancer. Read more.

Over the past few decades, there have been important advances in cancer therapeutics, including a shift from traditional cytotoxic…

Cannabidiol (CBD) comes from Cannabis sativa, which is a medicinal plant known to have several properties. Several types of extracts from…

As a medical student in Edinburgh, I was inspired by the opportunities in Edinburgh to combine clinical and basic science research in respiratory medicine.

I have always been incredibly interested in science and in trying to understand how things work. My first degree was in natural sciences at Cambridge, UK, where I specialised in neurobiology, and this exposed me to the beauty and rigor of basic science.

Vaccination is currently the most powerful tool for controlling the COVID-19 pandemic.1 In large randomised controlled trials, the approved vaccines have shown good efficacy and safety.2 However, there is increasing concern about the safety of the adenovirus-based COVID-19 vaccines of AstraZeneca (ChAdOx1 nCoV-19) and Janssen (Ad26.COV2.S).

The World Health Organization (WHO) has reported that an estimated 10.0 million people (range: 8.9–11.0 million) became ill with tuberculosis (TB) in 2019. There were an estimated 1.2 million TB deaths (range: 1.1–1.3 million) among people who were HIV-negative in 2019 and an additional 208,000 deaths (range: 177,000–242,000) among people who were HIV-positive.